Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Benazepril hydrochloride
Drug ID BADD_D00228
Description Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Indications and Usage Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].
Marketing Status approved; investigational
ATC Code C09AA07
DrugBank ID DB00542
KEGG ID D00620
MeSH ID C044946
PubChem ID 5362123
TTD Drug ID D0U3EC
NDC Product Code 51927-0104; 65862-116; 23155-749; 42291-162; 43063-679; 50090-3243; 51655-388; 53746-751; 63629-8035; 70771-1149; 65129-2021; 23155-750; 51407-463; 51655-065; 53746-752; 53746-754; 60760-352; 63187-500; 68788-7845; 70771-1150; 13612-0002; 65862-117; 71052-173; 23155-752; 51655-202; 65162-753; 68071-1026; 71205-320; 55154-4344; 63187-499; 70934-608; 71335-0011; 72162-1816; 30698-449; 43063-677; 50090-5751; 55154-4343; 65162-754; 68788-9313; 68788-9327; 70518-2125; 71335-1086; 50090-3775; 50268-109; 51407-465; 51655-617; 61919-756; 65162-751; 68071-2929; 70518-3171; 70518-3528; 71335-0457; 71335-0854; 42291-163; 43547-338; 50090-3359; 50268-110; 51407-462; 51407-464; 60760-351; 63187-393; 63187-906; 68788-6889; 70771-1148; 71335-1365; 44139-0026; 43547-336; 50090-5750; 53002-1233; 65862-118; 68788-6957; 70518-1640; 70518-3172; 70771-1151; 70934-483; 71335-0267; 71335-1299; 23155-751; 42291-161; 51655-755; 53746-753; 70934-983; 72189-110; 15308-0900; 17404-0016; 51927-0105; 58159-086; 65862-346; 30698-448; 43547-337; 50268-112; 53002-1248; 55700-291; 65162-752; 68071-1770; 70518-3074; 71205-244; 71335-0078; 22568-1136; 51927-0036; 64220-145; 30698-450; 43063-748; 43547-335; 50268-111; 51655-066
UNII N1SN99T69T
Synonyms benazepril | benazapril | benzazepril | Labopal | Lotensin | Cibacène | Cibacen | Briem | benazepril hydrochloride | CGS-14824-A | CGS-14824A
Chemical Information
Molecular Formula C24H29ClN2O5
CAS Registry Number 86541-74-4
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain08.01.08.002; 22.12.02.003; 02.02.02.011--Not Available
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.004--Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages